1. Sylw/Dadl › Ymchwil › Adolygwyd gan gymheiriaid
2. Cyhoeddwyd

   Challenges for economic evaluation of strategies to contain antimicrobial resistance

   Holmes, E. & Hughes, D., 27 Medi 2019, Yn: Antibiotics. 8, 4, 8 t., 166.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Sylw/Dadl › adolygiad gan gymheiriaid

3. Cyhoeddwyd

   Pharmacogenomics spotlight commentary: From the United Kingdom to global populations

   Magavern, E. F., Daly, A. K., Gilchrist, A. & Hughes, D., Rhag 2021, Yn: British Journal of Clinical Pharmacology. 87, 12, t. 4546-4548 3 t., 14917.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Sylw/Dadl › adolygiad gan gymheiriaid

4. Golygyddiad › Ymchwil › Adolygwyd gan gymheiriaid
5. Cyhoeddwyd

   Improving Medication Adherence Research Reporting: European Society for Patient Adherence, Compliance and Persistence Medication Adherence Reporting Guideline

   de Geest, S., Zullig, L., Dunbar-Jacobs, J., Hughes, D., Wilson, I. & Vrijens, B., Meh 2019, Yn: Journal of Cardiovascular Nursing. 34, 3, t. 199-200

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Golygyddiad › adolygiad gan gymheiriaid

6. Cyhoeddwyd

   Improving medication adherence research reporting: ESPACOMP Medication Adherence Reporting Guideline (EMERGE)

   de Geest, S., Zullig, L. L., Dunbar-Jacob, J., Hughes, D., Wilson, I. & Vrijens, B., 1 Ebr 2019, Yn: European Journal of Cardiovascular Nursing. 18, 4, t. 258-259 2 t.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Golygyddiad › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   Medication adherence research comes of age

   Wright, D. F. B., Sinnappah, K. A. & Hughes, D., Gorff 2023, Yn: British Journal of Clinical Pharmacology. 89, 7, t. 1914-1917

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Golygyddiad › adolygiad gan gymheiriaid

8. Cyhoeddwyd

   Medication adherence – key considerations for clinical pharmacologists

   Hughes, D., Ebr 2020, Yn: British Journal of Clinical Pharmacology. 86, 4, t. 628-629 2 t.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Golygyddiad › adolygiad gan gymheiriaid

9. Crynodeb Cyfarfod › Ymchwil › Adolygwyd gan gymheiriaid
10. Cyhoeddwyd

    Cost effectiveness analysis of treatments for children with uncontrolled asthma symptoms despite taking inhaled corticosteroids

    Culeddu, G., Sinha, I., Donegan, S., Maden, M., Cividini, S., Rose, K., Fulton, O., Turner, S., Tudor-Smith, C. & Hughes, D., 27 Hyd 2023, Yn: European Respiratory Journal. 62 , Supplement 67, PA 523.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Crynodeb Cyfarfod › adolygiad gan gymheiriaid

11. Cyhoeddwyd

    Patient preferences for outcomes in clinical trials: implications for medicines optimization

    Holmes, E., Marson, A. G. & Hughes, D., 8 Mai 2017, Yn: Trials. 18 (Suppl 1), O18, t. 192 1 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Crynodeb Cyfarfod › adolygiad gan gymheiriaid

12. Pennod › Ymchwil › Heb ei adolygu gan gymheiriaid
13. Cyhoeddwyd

    Approaches to pharmacoeconomic analysis

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 101-126

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

14. Cyhoeddwyd

    Drug evaluation and pharmocoeconomics.

    Hughes, D., Krska, J., Hughes, D. A., Winfield, A. J. (gol.), Rees, J. A. (gol.) & Smith, I. (gol.), 1 Ion 2009, Pharmaceutical Practice: 4th Edition.. 2009 gol. Churchill Livingstone, t. 185-198

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

15. Cyhoeddwyd

    Health economic aspects of patient non-compliance

    Hughes, D., Hughes, D. A., Davies, M. (gol.) & Kermani, F. (gol.), 1 Ion 2006, Patient Compliance: Sweetening the Pill. 2006 gol. Gower Publishing, t. 23-40

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

16. Cyhoeddwyd

    Modelling in health economics

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 141-154

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

17. Cyhoeddwyd

    The future challenges

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 167-174

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

18. Pennod › Ymchwil › Adolygwyd gan gymheiriaid
19. Cyhoeddwyd

    Review of resource-use measures in UK economic evaluations

    Ridyard, C. & Hughes, D., 2015, PSSRU Unit Costs of Health and Social Care 2015 . Curtis, L. & Burns, A. (gol.). University of Kent, Canterbury, t. 22-31 10 t.

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod › adolygiad gan gymheiriaid

20. Papur › Ymchwil › Heb ei adolygu gan gymheiriaid
21. Cyhoeddwyd

    A parenting programme for children at risk of developing conduct disorder: A cost-effectiveness analysis

    Hughes, D., Edwards, R. T., Ceilleachair, A., Bywater, T., Hughes, D. A. & Hutchings, J., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

22. Cyhoeddwyd

    A prototype agent-based model of antimalarial drug compliance

    Hughes, D., McKean, J., Rahlf, S., Shorter, H., Barnish, G., Paton, R., McBurney, P., Hughes, D. A. & Hastings, I., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

23. Cyhoeddwyd

    A single centre open phase IV study to evaluate the safety and tolerability of chlorproguanil-dapsone when dosed by defined height bands

    Hughes, D., Makanga, M., Winstanley, P. & Hughes, D. A., 1 Tach 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

24. Cyhoeddwyd

    A systematic review and empirical analysis of the relation between dose and duration of drug action.

    Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Ion 2009, t. TP40.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

25. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Medi 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

26. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

27. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Meh 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

28. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Mai 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

29. Cyhoeddwyd

    Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

30. Cyhoeddwyd

    Adherence with HAART: pharmacoeconomic considerations

    Hughes, D. & Hughes, D. A., 1 Meh 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

31. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Gorff 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

32. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

33. Cyhoeddwyd

    Adverse drug reactions: analysis by regulatory authorities and by economists

    Hughes, D. & Hughes, D. A., 1 Ebr 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

34. Cyhoeddwyd

    Assessing the association between compliance and therapeutic failure for antiretroviral drugs in HIV positive patients

    Hughes, D. & Hughes, D. A., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

35. Cyhoeddwyd

    Assessing the association between compliance and therapeutic failure for antiretroviral drugs in HIV positive patients

    Hughes, D., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

36. Cyhoeddwyd

    Assessment, Determinants & Economics of Medication Compliance & Persistence Forum.

    Hughes, D., Hughes, D. A., Gwadry-Sridhar, F. & Manias, E., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

37. Cyhoeddwyd

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 Mai 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

38. Cyhoeddwyd

    Biological agents for the management of Crohn's disease in adults: a systematic review, meta-analysis and multiple treatment comparison

    Hughes, D., Hughes, D. A., Kikuchi, T. & Bodger, K., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

39. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

40. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

41. Cyhoeddwyd

    Clinical and econnomic importance of completion of therapy in the treatment of LRTIs

    Hughes, D. & Hughes, D. A., 1 Medi 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

42. Cyhoeddwyd

    Comparisons between the medication possession ratio (MPR) and gaps measures of medication compliance: are we selling ourselves short by relying on the MPR?

    Hughes, D., Nichol, M., Manias, E., Hughes, D. A. & Schabert, V. F., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

43. Cyhoeddwyd

    Cost of non-compliance and non-persistence with medications for diabetes mellitus

    Hughes, D., Salas, M., Hughes, D. A., Lebmeier, M. & Vardeva, K., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

44. Cyhoeddwyd

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

45. Cyhoeddwyd

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

46. Cyhoeddwyd

    Cost-effectiveness considerations in pharmacogenetics.

    Hughes, D. & Hughes, D. A., 1 Ion 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

47. Cyhoeddwyd

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

48. Cyhoeddwyd

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

49. Cyhoeddwyd

    Costs of non-compliance to antipsychotic medications among patients with schizophrenia.

    Hughes, D., Hughes, D. A., Salas, M., Zuluaga, A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Mai 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

50. Cyhoeddwyd

    Current assessment of risk-benefit by regulators: Is it time to introduce decision analyses?

    Hughes, D., Hughes, D. A., Pirmohamed, M. & Bayoumi, A., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

51. Cyhoeddwyd

    Drug compliance and pharmaceconomics

    Hughes, D. & Hughes, D. A., 1 Rhag 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

52. Cyhoeddwyd

    Economic considerations for market access of new health technologies: A case study of pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Chwef 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

53. Cyhoeddwyd

    Economic considerations for pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Meh 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

54. Cyhoeddwyd

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

55. Cyhoeddwyd

    Economic evaluation of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

56. Cyhoeddwyd

    Economic evaluation of on-demand maintenance therapy with proton pump inhibitors in patients with symptomatic gastroesophageal reflux disease - a Monte-Carlo analysis for Italy

    Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Hyd 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur